Stocks360

Provexis plc (PXS.L)

Stock analysis · LSE · Healthcare · Drug Manufacturers - Specialty & Generic

Share: Facebook X WhatsApp SMS

Get deeper signals and personalized alerts

Free account signup in under 60 seconds

Create free account → I already have an account
Market Cap
N/A
PE (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
N/A
Beta
0.68
Day Range
N/A
52-wk Range
N/A
Avg Volume
N/A
Volume
N/A

Provexis plc (PXS.L) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About Provexis plc

Operating globally, Provexis plc, along with its associated companies, specializes in the creation, licensing, and commercialization of functional foods, medical nutritional products, and dietary supplements. A key offering is Fruitflow, a unique tomato extract designed to reduce the tendency for abnormal blood clot formation, which is linked to severe cardiovascular conditions such as heart attacks and strokes. This versatile extract is available in syrup and powder formats for integration into various food and beverage items, as well as dietary supplements. The company also provides Fruitflow + Omega-3, a capsule-based supplement aimed at fostering healthy blood circulation and supporting normal cardiac function. Provexis plc holds a strategic collaboration agreement with By-Health Co., Ltd. Its products are distributed through both physical retail channels and digital online platforms. Founded in 1999, Provexis plc has its headquarters situated in Reading, United Kingdom.

Peers

Recent News

  • No recent news available.

Related

Browse more tickers: sitemap